Michael D. Harvey

Michael D. Harvey, PhD is a senior executive with 20 years of experience in drug development. His expertise in various therapeutic areas includes musculoskeletal rare diseases, oncology, as well as infectious diseases. As an experienced leader in the biotech start-up space, he successfully advanced programs throughout nonclinical and clinical development and led high performing cross-functional teams to deliver innovative therapies to patients. Over his career, Dr. Harvey demonstrated strong abilities in strategic planning, execution in a fast-paced environment and alliance management, including pharma partner collaborations.

Prior to joining Inversago, Dr. Harvey was Vice President, Drug Development and Montreal Site Head at Ipsen (formerly Clementia Pharmaceuticals Inc.). He previously assumed increasing managing roles at Thallion Pharmaceuticals and several other biotech companies. Dr. Harvey holds a BSc in Biology and a PhD in Bioanalytical Chemistry, both from Concordia University (Montreal, Canada).